A Phase 2 interventional study of LW402 and LW402 placebo in Atopic Dermatitis (AD), sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-02.
Sponsored by Shanghai Longwood Biopharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.
Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 111th largest by enrollment of the 190 interventional ones that give a count, is one of 39 that started in 2023, is one of 58 in phase 2, and was the 164th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:
Galderma R&D · Sites in China
Ages 12+
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Sites in China
Ages 18–75
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 2–11
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–75
QuantX Biosciences, Inc. · Sites in China
Ages 18 mo–65 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 53 · Phase 2 76 · Phase 3 63 · Phase 4 5
First in 2011; this study’s year is marked. 39 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 144 is above the median of 82 across 1,246 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 164 across the 190 interventional studies, 472 across the 16 observational. Of the 114 that completed or were terminated, 22 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
183 of 206 have an industry lead sponsor. The 10 most frequent:
Shanghai Longwood Biopharmaceuticals Co., Ltd. is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Shanghai Longwood Biopharmaceuticals Co., Ltd. has 2 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
27 of the studies in Dermatitis, Atopic with a site in China that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06775860Phase 3Beijing InnoCare Pharma Tech Co., Ltd.ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis | 2026-11-25 |
| NCT07540442Phase 3Shanghai Mabgeek Biotech.Co.LtdA Phase III Study of MG-K10 in Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-01-05 |
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
| NCT06880276Phase 3Qilu Pharmaceutical Co., Ltd.Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis | 2027-03 |
| NCT07386743Phase 3Jiangsu Genscend Biopharmaceutical Co., LtdA Phase III Study of GS101 Injection to Dupixent® | 2027-04 |
Add all 27 to your calendar (.ics) → With an account.
Among the 206 studies in Dermatitis, Atopic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double blind, placebo-controlled phase 2 study to evaluate the efficacy, safety, PK and PD ofLW402 in patients with moderate-to-severe atopic dermatitis.
The study consists of an up-to-4-week screening period, a 12-week double-blind treatment period and a 4-week safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
pregnancy. Other.
LW402 administered orally, BID (low dose)
Drug: LW402
LW402 administered orally, BID (medium dose)
Drug: LW402
LW402 administered orally, BID (high dose)
Drug: LW402
LW402 placebo administered orally, BID
Drug: LW402 placebo
LW402 tablets
LW402 placebo tablets
Proportion of participants achieving EASI-50 at week 12
Proportion of participants achieving EASI-50 (≥50% reduction from baseline in Eczema Area and Severity Index score) at week 12. The EASI is a composite index with scores ranging from 0 to 72. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) will each be assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe).
Time frame: 12 weeks
Proportion of participants achieving EASI-75 at week 12
Proportion of participants achieving EASI-75 (≥75% reduction from baseline in Eczema Area and Severity Index score) at week 12.
Time frame: 12 weeks
Proportion of participants with IGA score of 0 or 1 and a reduction of IGA score by ≥2 points from baseline at week 12
Proportion of participants with Investigator's Global Assessment (IGA) score of 0 or 1 and a reduction of IGA score by ≥2 points from baseline at week 16. IGA is an assessment instrument used in clinical studies to rate the severity of AD globally, based on a 6-point scale ranging from 0 (clear) to 5 (very severe).
Time frame: 12 weeks
Incidence of adverse events (AEs), abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.
Incidence of adverse events (AEs), abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.
Time frame: 16 weeks
PD: pSTAT3 and pSTAT5 inhibition rates
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2023 to primary completion in Sep 2024, 16 months.
Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 16 months is above that.
Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LW402
Shanghai Longwood Biopharmaceuticals Co., Ltd.